Medpace Holdings (MEDP) Other Accumulated Expenses (2015 - 2026)
Medpace Holdings' (MEDP) quarterly Other Accumulated Expenses came in at $42.1 million in Q2 2026, down 6.19% on a YoY basis from $44.9 million in Q2 2025, and down 12.61% quarter-over-quarter from $48.2 million in Q1 2026.
Analysis
Medpace Holdings (MEDP) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
Medpace Holdings (MEDP) has reported Other Accumulated Expenses for 12 consecutive years, with $42.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Accumulated Expenses fell 6.19% year-over-year to $42.1 million; the trailing twelve-month figure through Jun 2026 stood at $42.1 million (down 6.19% YoY), and the FY2025 full-year result was $52.8 million, down 1.49% from the prior year.
- Other Accumulated Expenses declined to $42.1 million in Q2 2026 per MEDP's latest filing, from $48.2 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $62.5 million in Q1 2023 and bottomed at $25.9 million in Q2 2022.
- Historically, Other Accumulated Expenses has averaged $43.6 million across 5 years, with a median of $43.4 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 96.94% in 2023, then slipped 28.65% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $47.5 million in 2022, then declined by 14.95% to $40.4 million in 2023, then jumped by 32.62% to $53.6 million in 2024, then slipped by 1.49% to $52.8 million in 2025, then retreated by 20.31% to $42.1 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $42.1 million, $48.2 million, and $52.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.10 Mn |
| Mar 31, 2026 | 48.18 Mn |
| Dec 31, 2025 | 52.83 Mn |
| Sep 30, 2025 | 54.32 Mn |
| Jun 30, 2025 | 44.88 Mn |
| Mar 31, 2025 | 56.18 Mn |
| Dec 31, 2024 | 53.63 Mn |
| Sep 30, 2024 | 37.35 Mn |
| Jun 30, 2024 | 34.62 Mn |
| Mar 31, 2024 | 44.62 Mn |
| Dec 31, 2023 | 40.44 Mn |
| Sep 30, 2023 | 35.96 Mn |
| Jun 30, 2023 | 41.35 Mn |
| Mar 31, 2023 | 62.54 Mn |
| Dec 31, 2022 | 47.55 Mn |
| Sep 30, 2022 | 30.88 Mn |
| Jun 30, 2022 | 25.90 Mn |
| Mar 31, 2022 | 31.76 Mn |
| Dec 31, 2021 | 27.61 Mn |
| Sep 30, 2021 | 30.07 Mn |